Skov Marianne, Hansen Christine Rønne, Pressler Tacjana
Department of Pediatrics, Rigshospitalet, Copenhagen, Denmark.
Pediatrics Skåne University Hospital, Lund, Sweden.
APMIS. 2019 May;127(5):352-360. doi: 10.1111/apm.12915. Epub 2019 Feb 14.
Cystic fibrosis (CF) is a severe, monogenic, autosomal recessive disease caused by mutations in the CFTR (cystic fibrosis transmembrane regulator) gene, where disturbed chloride and bicarbonate transportation in epithelial cells results in a multiorgan disease with primarily pulmonary infections and pancreatic insufficiency. In 1968, the Copenhagen CF Center was established, and centralized care of CF patients with monthly control was introduced. Close monitoring and treatment of Pseudomonas lung infection as well as segregation of patients with different infection status improved the clinical outcome as well as survival. Prophylactic basic treatment as well as infection treatments follow specific algorithms. A variety of comorbidities have all along the pulmonary infection control necessitated personalized care, adjusted to the patients' phenotype. With the introduction of CFTR modulators, the treatment has shifted from prophylactic, symptomatic type toward a new era of precision medicine targeting the basic defect according to the patients' CFTR genotype. Future directions will focus on further improvement of the CFTR modulators and gene therapy, as well as modifier genes and CF phenotype.
囊性纤维化(CF)是一种严重的单基因常染色体隐性疾病,由CFTR(囊性纤维化跨膜传导调节因子)基因突变引起,上皮细胞中氯化物和碳酸氢盐运输紊乱导致多器官疾病,主要表现为肺部感染和胰腺功能不全。1968年,哥本哈根囊性纤维化中心成立,并引入了对囊性纤维化患者的集中护理及每月检查。对铜绿假单胞菌肺部感染的密切监测和治疗以及对不同感染状态患者的隔离改善了临床结果和生存率。预防性基础治疗以及感染治疗遵循特定算法。在整个肺部感染控制过程中,多种合并症都需要根据患者的表型进行个性化护理。随着CFTR调节剂的引入,治疗已从预防性、对症治疗转向根据患者CFTR基因型针对基本缺陷的精准医学新时代。未来的方向将集中在进一步改进CFTR调节剂和基因治疗,以及修饰基因和CF表型。